HutchMed Enters Licensing Deal with GSK for Cancer Therapy, Could Generate Up to $1.295 Billion
Hutchemd has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for HMPL-A830, a potential cancer therapy targeting KRAS and EGFR mutations. The deal could bring up to $1.295 billion in proceeds for the Chinese biopharmaceutical company. Hutchemd will receive an upfront payment of $110 million as part of this agreement. The collaboration involves GSK gaining exclusive rights to develop, manufacture, and commercialize HMPL-A830 globally outside China. This marks a significant milestone for Hutchemd in advancing its pipeline beyond the Chinese market through strategic partnerships with global pharmaceutical leaders like GSK.
